Related Experiment Videos
[Ototoxicity of micronomicin sulfate--audiometric assessment]
Abstract:
Micronomicin sulfate (MCR) is a new aminoglycoside antibiotic, and its antibacterial spectrum is similar to that of gentamicin (GM). According to the animal test, MCR has less ototoxicity than other aminoglycoside antibiotics such as GM. To check its clinical ototoxicity, MCR was given intramuscularly to 20 patients at dose of 120--240 mg/day, respectively for 2--8 days, and audiometry was carried out before and after administration of MCR. No evident change was detected between the preadministration hearing levels and the postadministration hearing levels. These data suggest that MCR is sufficiently safe in ototoxicity within dose of 120 mg/day for 4 days.
Insights
Micronomicin sulfate (MCR), a new aminoglycoside antibiotic, showed minimal ototoxicity in patients. Clinical trials suggest MCR is safe at doses up to 120 mg/day for 4 days, with no significant hearing changes observed.
Area of Science:
- Pharmacology
- Ototoxicology
- Infectious Diseases
Context:
- Micronomicin sulfate (MCR) is a novel aminoglycoside antibiotic with a spectrum similar to gentamicin (GM).
- Preclinical animal studies indicated lower ototoxicity for MCR compared to other aminoglycosides.
- Clinical evaluation was necessary to confirm MCR's safety profile in humans.
Purpose:
- To assess the clinical ototoxicity of micronomicin sulfate (MCR) in human patients.
- To compare the ototoxic potential of MCR with established aminoglycoside antibiotics like gentamicin.
- To establish safe dosage and duration limits for MCR administration based on audiological assessments.
Summary:
- Twenty patients received intramuscular MCR at doses of 120-240 mg/day for 2-8 days.
- Audiometry was performed before and after MCR administration to monitor hearing function.
- No significant changes in hearing levels were detected post-administration, indicating a favorable safety profile.
Impact:
- Micronomicin sulfate (MCR) demonstrates a potentially safer ototoxic profile than other aminoglycosides.
- Findings support the use of MCR at doses up to 120 mg/day for 4 days with minimal risk of hearing damage.
- This research contributes to the understanding of aminoglycoside safety and informs clinical antibiotic selection.